<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03475173</url>
  </required_header>
  <id_info>
    <org_study_id>201611825</org_study_id>
    <nct_id>NCT03475173</nct_id>
  </id_info>
  <brief_title>New Non-invasive Modalities for Assessing Retinal Structure and Function</brief_title>
  <official_title>New Non-invasive Modalities for Assessing Retinal Structure and Function:Preliminary Investigation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Randy Kardon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Iowa</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study investigates a new technology to assess the structure and function inside the eye.&#xD;
      Retinal imaging of subjects with inner and outer retinal defects to detect areas of abnormal&#xD;
      structure and function compared to other visual function tests.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 6, 2019</start_date>
  <completion_date type="Anticipated">March 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ocular Blood Flow</measure>
    <time_frame>1 day</time_frame>
    <description>imaging the movement of blood through blood vessels in retina and optic nerve</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Ischemic Optic Neuropathy</condition>
  <condition>Branch Retinal Artery Occlusion</condition>
  <condition>Hemianopia</condition>
  <condition>Leber Hereditary Optic Neuropathy</condition>
  <condition>Acute Zonal Occult Outer Retinopathy</condition>
  <arm_group>
    <arm_group_label>Laser Speckle Blood Flow Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>LSFG-NAVI</intervention_name>
    <description>laser-speckle blood flow of ocular arteries and veins</description>
    <arm_group_label>Laser Speckle Blood Flow Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Controls:&#xD;
&#xD;
        Inclusion:&#xD;
&#xD;
        Normal eye exam in last 2 years&#xD;
&#xD;
        Exclusion:&#xD;
&#xD;
        Cataract or media opacity that would degrade the imaging of the retina. Mild cataracts are&#xD;
        okay. Any abnormalities of the retina or optic nerve that could affect metabolism of the&#xD;
        retina outside of normal.&#xD;
&#xD;
        Subjects with Inner Retina Defect:&#xD;
&#xD;
        Inclusion:&#xD;
&#xD;
        Defined structural defect to include those with Ischemic optic neuropathy, branch retinal&#xD;
        artery occlusion (BRAO), hemianopia or visual field defect that respects the vertical&#xD;
        meridian, inherited mitochondrial optic neuropathies such as Leber's and Dominant Optic&#xD;
        Neuropathy, other retinopathies or optic neuropathies.&#xD;
&#xD;
        Exclusion:&#xD;
&#xD;
        Cataract or media opacity that would degrade the imaging of the retina. Mild cataracts are&#xD;
        okay.&#xD;
&#xD;
        Subjects with Outer Retinal Defect:&#xD;
&#xD;
        Inclusion:&#xD;
&#xD;
        AZOOR (acute zonal occult outer retinopathy) or other focal or diffuse outer photoreceptor&#xD;
        loss of function&#xD;
&#xD;
        Exclusion:&#xD;
&#xD;
        Cataract or media opacity that would degrade the imaging of the retina. Mild cataracts are&#xD;
        okay.&#xD;
&#xD;
        The 450 total is to allow for exclusion of some subjects or in the event that the enrolled&#xD;
        subject blinks too much or cannot fixate on a visual target adequately to maintain the same&#xD;
        eye position during the short imaging interval. We hope to have a total of 450 (50 controls&#xD;
        and 400 patients)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Randy H Kardon, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Iowa Department of Ophthalmology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Julie K Nellis, BSN</last_name>
    <phone>319-356-8299</phone>
    <email>julie-nellis@uiowa.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jan M Full, BSN</last_name>
    <phone>319-356-8299</phone>
    <email>jan-full@uiowa.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Iowa Department of Ophthalmology</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Denise L Rettig, MHA. MBA</last_name>
      <phone>319-356-2866</phone>
      <phone_ext>5849</phone_ext>
      <email>denise-rettig@uiowa.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>March 16, 2018</study_first_submitted>
  <study_first_submitted_qc>March 16, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 23, 2018</study_first_posted>
  <last_update_submitted>May 4, 2021</last_update_submitted>
  <last_update_submitted_qc>May 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Iowa</investigator_affiliation>
    <investigator_full_name>Randy Kardon</investigator_full_name>
    <investigator_title>Dr. Randy Kardon M.D. Ph.D Professor and Director of Neuro-ophthalmology</investigator_title>
  </responsible_party>
  <keyword>Optic Neuropathy</keyword>
  <keyword>, Retinopathy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Nervous System Diseases</mesh_term>
    <mesh_term>Optic Nerve Diseases</mesh_term>
    <mesh_term>Optic Neuropathy, Ischemic</mesh_term>
    <mesh_term>Optic Atrophy, Hereditary, Leber</mesh_term>
    <mesh_term>Hemianopsia</mesh_term>
    <mesh_term>Retinal Diseases</mesh_term>
    <mesh_term>Retinal Artery Occlusion</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

